Kawabe K, Abe S, Kanda T, Tei K
Urol Int. 1986;41(1):16-20. doi: 10.1159/000281150.
Oxybutynin chloride has been clinically used for the relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflex neurogenic bladder in the USA. The present clinical and urodynamic studies were the first meticulously in patients with uninhibited neurogenic and reflex neurogenic bladder in Japan. A single oral dose of oxybutynin chloride (3 or 6 mg) did not induce any change either in subjective symptoms or in urodynamic studies; however, in the continual administration study, 7 of 9 patients showed an improvement in the symptoms associated with voiding. The drug reduced urinary frequency, urgency and incontinence, and significantly increased the volumes at the first desire to void (FDV) and maximum desire to void (MDV) in cystometry. Furthermore, no serious adverse reactions were observed, and hence the drug seems to be of clinical significance.
在美国，氯化奥昔布宁已被临床用于缓解无抑制性神经源性和反射性神经源性膀胱患者排尿相关症状。目前的临床和尿动力学研究在日本尚属首次针对无抑制性神经源性和反射性神经源性膀胱患者进行的细致研究。单次口服氯化奥昔布宁（3毫克或6毫克）在主观症状或尿动力学研究中均未引起任何变化；然而，在持续给药研究中，9名患者中有7名排尿相关症状有所改善。该药物减少了尿频、尿急和尿失禁，并显著增加了膀胱测压中首次排尿欲望（FDV）和最大排尿欲望（MDV）时的尿量。此外，未观察到严重不良反应，因此该药物似乎具有临床意义。
